NCT01262794

Pharmacokinetic (PK)/Pharmacodynamic (PD), Study of Single-dose Subcutaneous CDP6038 in Healthy Japanese Male Subjects

A Phase 1, Randomized, Double-blind, Placebo Controlled, Single-center, Single Dose Study to Evaluate the Safety and Tolerability, Pharmacokinetics and Pharmacodynamics of CDP6038 Administered Subcutaneously to Healthy Japanese Males

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 20 (actual)
• Sponsor: UCB Pharma · Industry
• Sex: Male
• Age: 20 Years – 60 Years
• Healthy volunteers: Accepted

Summary

To evaluate the safety and tolerability of CDP6038 following single dose subcutaneous (sc) administration of CDP6038 to Japanese subjects. To evaluate the Pharmacokinetics of CDP6038 following single dose sc administration of CDP6038 to Japanese subjects

Conditions

• Healthy Volunteers

Interventions

Type	Name	Description
BIOLOGICAL	CDP6038	100 mg/mL solution for injection, single dose
BIOLOGICAL	Placebo	0.9% sodium chloride for injection Single-dose

Timeline

• Start date: 2010-11-01
• Primary completion: 2011-09-01
• Completion: 2011-09-01
• First posted: 2010-12-17
• Last updated: 2011-09-27

Locations

1 site across 1 country: United Kingdom